Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:VRP
CUSIPN/A
Phone+44-20-32834200
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-30.13%
Return on Assets-26.97%
Miscellaneous
EmployeesN/A
Outstanding Shares105,020,000
Market Cap£160.79
Verona Pharma (LON:VRP) Frequently Asked Questions
What is Verona Pharma's stock symbol?
Verona Pharma trades on the London Stock Exchange (LON) under the ticker symbol "VRP."
How were Verona Pharma's earnings last quarter?
Verona Pharma Plc (LON:VRP) issued its quarterly earnings results on Tuesday, May, 8th. The company reported ($14.50) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($23.70) by $9.20. View Verona Pharma's Earnings History.
What price target have analysts set for VRP?
3 brokerages have issued twelve-month price objectives for Verona Pharma's stock. Their forecasts range from GBX 160 to GBX 348. On average, they anticipate Verona Pharma's stock price to reach GBX 252.67 in the next year. This suggests a possible upside of 100.5% from the stock's current price. View Analyst Ratings for Verona Pharma.
What is the consensus analysts' recommendation for Verona Pharma?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Verona Pharma's key competitors?
Some companies that are related to Verona Pharma include Mesoblast (MEOBF), Emerald Health Therapeutics (EMH), Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Neptune Technologies & Bioressources (NEPT), Monash IVF Group (MVF), ABcann Global (ABCN), Horizon Discovery Group (HZD), IMV (IMV) and Faron Pharmaceuticals Oy (FARN).
Who are Verona Pharma's key executives?
Verona Pharma's management team includes the folowing people:
- Dr. Jan-Anders Karlsson, Chief Exec. Officer & Exec. Director (Age 63)
- Mr. Piers John Morgan MA, ACA, Chief Financial Officer (Age 52)
- Ms. Claire Louise Poll, Legal Counsel (Age 51)
- Dr. Peter Spargo Ph.D., Sr. VP of CMC (Age 56)
- Dr. Kenneth Newman, Chief Medical Officer (Age 60)
Has Verona Pharma been receiving favorable news coverage?
News headlines about VRP stock have been trending somewhat positive on Sunday, Accern reports. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Verona Pharma earned a coverage optimism score of 0.13 on Accern's scale. They also gave news stories about the company an impact score of 46.42 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Verona Pharma?
Shares of VRP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Verona Pharma's stock price today?
One share of VRP stock can currently be purchased for approximately GBX 126.
How big of a company is Verona Pharma?
Verona Pharma has a market capitalization of £160.79 million.
How can I contact Verona Pharma?
Verona Pharma's mailing address is 3 More London Riverside, LONDON, SE1 2RE, United Kingdom. The company can be reached via phone at +44-20-32834200.
MarketBeat Community Rating for Verona Pharma (LON VRP)
MarketBeat's community ratings are surveys of what our community members think about Verona Pharma and other stocks. Vote "Outperform" if you believe VRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
